Protox Completes Enrollment of Phase 2 BPH Trial ...
T-Net British Columbia: 4 views since Wednesday, September 3, 2008 at 11:43 AM
Vancouver, BC, September 3, 2008--(T-Net)--Protox Therapeutics Inc. (TSX:PRX), a leader in the development of receptor targeted fusion proteins, announced today that it has completed enrollment of patients for its Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia, a common and bothersome urological condition that affects more than 1 million men in Canada and ...

Published in: Procedures and Therapies